secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2026-04-27T23:59:59+00:00
Accession:  0001193125-26-179243
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 2.03, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin completes $4.8B acquisition of Amicus Therapeutics; adds Galafold, Pombiliti+Opfolda
--------------------------------------------------------------------------------

- Acquired Amicus for $14.50/share in cash; total equity value ~$4.8B.
- Adds Galafold (Fabry), Pombiliti+Opfolda (Pompe) and DMX-200 (FSGS) to commercial portfolio.
- Financed via $2.8B in new term loans ($2.0B Term B, $800M Term A) and 2034 notes.
- Expects to provide updated FY2026 guidance on May 4 earnings call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000119312526179243/0001193125-26-179243-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000119312526179243/d113922d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-179243

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer